Cargando…

Analysis of SARS-CoV-2 reverse transcription-quantitative polymerase chain reaction cycle threshold values vis-à-vis anti-SARS-CoV-2 antibodies from a high incidence region

OBJECTIVES: To examine the relationship between antibody status and cycle threshold (Ct) values, the prognostic value of the latter for COVID-19 patients, and the inter-assay comparability of SARS-CoV-2 Ct values. METHODS: In 347 COVID-19 inpatients, SARS-CoV-2 Ct values (via reverse transcription-q...

Descripción completa

Detalles Bibliográficos
Autores principales: Markewitz, Robert, Torge, Antje, Wandinger, Klaus-Peter, Pauli, Daniela, Dargvainiene, Justina, Franke, Andre, Bujanda, Luis, Marimón, José Maria, Banales, Jesus M., Gutierrez-Stampa, María A., Nafría, Beatriz, Junker, Ralf
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8278831/
https://www.ncbi.nlm.nih.gov/pubmed/34273511
http://dx.doi.org/10.1016/j.ijid.2021.07.014
_version_ 1783722341209997312
author Markewitz, Robert
Torge, Antje
Wandinger, Klaus-Peter
Pauli, Daniela
Dargvainiene, Justina
Franke, Andre
Bujanda, Luis
Marimón, José Maria
Banales, Jesus M.
Gutierrez-Stampa, María A.
Nafría, Beatriz
Junker, Ralf
author_facet Markewitz, Robert
Torge, Antje
Wandinger, Klaus-Peter
Pauli, Daniela
Dargvainiene, Justina
Franke, Andre
Bujanda, Luis
Marimón, José Maria
Banales, Jesus M.
Gutierrez-Stampa, María A.
Nafría, Beatriz
Junker, Ralf
author_sort Markewitz, Robert
collection PubMed
description OBJECTIVES: To examine the relationship between antibody status and cycle threshold (Ct) values, the prognostic value of the latter for COVID-19 patients, and the inter-assay comparability of SARS-CoV-2 Ct values. METHODS: In 347 COVID-19 inpatients, SARS-CoV-2 Ct values (via reverse transcription-quantitative polymerase chain reaction) on admission were compared between 2 assays and correlated with the antibody response (in the course of the disease), the clinical course and the time since onset of symptoms. RESULTS: Ct values for 2 of 3 target genes showed significant differences between the 2 assays used (P=0.012 and P<0.0001). Ct values were significantly higher for antibody positive patients (P<0.0001) and positively correlated with the amount of time since onset of symptoms (R: 0.332–0.363; P<0.001). Patients with fatal outcomes showed higher viral loads than survivors (P<0.0001). CONCLUSIONS: Ct values depend strongly on assay used and target gene examined and should not be used as quantitative values to guide therapeutic or diagnostic decisions. The inverse association between antibody status and viral load suggests that antibodies contribute to the elimination of the virus, independent of the outcome, which is influenced by the viral load on admission and might depend more strongly on other parts of the immune response.
format Online
Article
Text
id pubmed-8278831
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
record_format MEDLINE/PubMed
spelling pubmed-82788312021-07-20 Analysis of SARS-CoV-2 reverse transcription-quantitative polymerase chain reaction cycle threshold values vis-à-vis anti-SARS-CoV-2 antibodies from a high incidence region Markewitz, Robert Torge, Antje Wandinger, Klaus-Peter Pauli, Daniela Dargvainiene, Justina Franke, Andre Bujanda, Luis Marimón, José Maria Banales, Jesus M. Gutierrez-Stampa, María A. Nafría, Beatriz Junker, Ralf Int J Infect Dis Article OBJECTIVES: To examine the relationship between antibody status and cycle threshold (Ct) values, the prognostic value of the latter for COVID-19 patients, and the inter-assay comparability of SARS-CoV-2 Ct values. METHODS: In 347 COVID-19 inpatients, SARS-CoV-2 Ct values (via reverse transcription-quantitative polymerase chain reaction) on admission were compared between 2 assays and correlated with the antibody response (in the course of the disease), the clinical course and the time since onset of symptoms. RESULTS: Ct values for 2 of 3 target genes showed significant differences between the 2 assays used (P=0.012 and P<0.0001). Ct values were significantly higher for antibody positive patients (P<0.0001) and positively correlated with the amount of time since onset of symptoms (R: 0.332–0.363; P<0.001). Patients with fatal outcomes showed higher viral loads than survivors (P<0.0001). CONCLUSIONS: Ct values depend strongly on assay used and target gene examined and should not be used as quantitative values to guide therapeutic or diagnostic decisions. The inverse association between antibody status and viral load suggests that antibodies contribute to the elimination of the virus, independent of the outcome, which is influenced by the viral load on admission and might depend more strongly on other parts of the immune response. The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2021-09 2021-07-14 /pmc/articles/PMC8278831/ /pubmed/34273511 http://dx.doi.org/10.1016/j.ijid.2021.07.014 Text en © 2021 The Author(s) Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Markewitz, Robert
Torge, Antje
Wandinger, Klaus-Peter
Pauli, Daniela
Dargvainiene, Justina
Franke, Andre
Bujanda, Luis
Marimón, José Maria
Banales, Jesus M.
Gutierrez-Stampa, María A.
Nafría, Beatriz
Junker, Ralf
Analysis of SARS-CoV-2 reverse transcription-quantitative polymerase chain reaction cycle threshold values vis-à-vis anti-SARS-CoV-2 antibodies from a high incidence region
title Analysis of SARS-CoV-2 reverse transcription-quantitative polymerase chain reaction cycle threshold values vis-à-vis anti-SARS-CoV-2 antibodies from a high incidence region
title_full Analysis of SARS-CoV-2 reverse transcription-quantitative polymerase chain reaction cycle threshold values vis-à-vis anti-SARS-CoV-2 antibodies from a high incidence region
title_fullStr Analysis of SARS-CoV-2 reverse transcription-quantitative polymerase chain reaction cycle threshold values vis-à-vis anti-SARS-CoV-2 antibodies from a high incidence region
title_full_unstemmed Analysis of SARS-CoV-2 reverse transcription-quantitative polymerase chain reaction cycle threshold values vis-à-vis anti-SARS-CoV-2 antibodies from a high incidence region
title_short Analysis of SARS-CoV-2 reverse transcription-quantitative polymerase chain reaction cycle threshold values vis-à-vis anti-SARS-CoV-2 antibodies from a high incidence region
title_sort analysis of sars-cov-2 reverse transcription-quantitative polymerase chain reaction cycle threshold values vis-à-vis anti-sars-cov-2 antibodies from a high incidence region
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8278831/
https://www.ncbi.nlm.nih.gov/pubmed/34273511
http://dx.doi.org/10.1016/j.ijid.2021.07.014
work_keys_str_mv AT markewitzrobert analysisofsarscov2reversetranscriptionquantitativepolymerasechainreactioncyclethresholdvaluesvisavisantisarscov2antibodiesfromahighincidenceregion
AT torgeantje analysisofsarscov2reversetranscriptionquantitativepolymerasechainreactioncyclethresholdvaluesvisavisantisarscov2antibodiesfromahighincidenceregion
AT wandingerklauspeter analysisofsarscov2reversetranscriptionquantitativepolymerasechainreactioncyclethresholdvaluesvisavisantisarscov2antibodiesfromahighincidenceregion
AT paulidaniela analysisofsarscov2reversetranscriptionquantitativepolymerasechainreactioncyclethresholdvaluesvisavisantisarscov2antibodiesfromahighincidenceregion
AT dargvainienejustina analysisofsarscov2reversetranscriptionquantitativepolymerasechainreactioncyclethresholdvaluesvisavisantisarscov2antibodiesfromahighincidenceregion
AT frankeandre analysisofsarscov2reversetranscriptionquantitativepolymerasechainreactioncyclethresholdvaluesvisavisantisarscov2antibodiesfromahighincidenceregion
AT bujandaluis analysisofsarscov2reversetranscriptionquantitativepolymerasechainreactioncyclethresholdvaluesvisavisantisarscov2antibodiesfromahighincidenceregion
AT marimonjosemaria analysisofsarscov2reversetranscriptionquantitativepolymerasechainreactioncyclethresholdvaluesvisavisantisarscov2antibodiesfromahighincidenceregion
AT banalesjesusm analysisofsarscov2reversetranscriptionquantitativepolymerasechainreactioncyclethresholdvaluesvisavisantisarscov2antibodiesfromahighincidenceregion
AT gutierrezstampamariaa analysisofsarscov2reversetranscriptionquantitativepolymerasechainreactioncyclethresholdvaluesvisavisantisarscov2antibodiesfromahighincidenceregion
AT nafriabeatriz analysisofsarscov2reversetranscriptionquantitativepolymerasechainreactioncyclethresholdvaluesvisavisantisarscov2antibodiesfromahighincidenceregion
AT junkerralf analysisofsarscov2reversetranscriptionquantitativepolymerasechainreactioncyclethresholdvaluesvisavisantisarscov2antibodiesfromahighincidenceregion